Intellect Neurosciences Inc. (fka ILNS)

[itwillgetbetter]

Doubt a pr is worthy just for that.As far as one stating shares being unrestricted due to the restructure it was Jan 25 from my understanding.

I doubt you see alot of insiders converting past B,C,D,E shares at about .15 cents on the dollar imho no matter what one claims.Just read the SEC filings them shares were also reduced by the 250 to 1 reverse.

You got a super low SS restructured company and the way I read it 3 ongoing trials that the mods want sticky per others request.The GSK I feel is apart but one would have to be a scientist regarding the compound as we talked about but as of today I never seen any filing public notice that license was terminated by either party.


Its sad when one can never find anything positive regarding Intellect.Tau is a major factor also beleive me others have told me so outside the company.No reason to lie and I'm not pumping.If the science is there its all good if not throw the dish water out its that simple.Time will tell.

Also regarding Elliot time will tell.I've high hopes is all I can say.Don't think the man is working 24/7 trying to pump something he almost never pr's or updates on.My ponit give the man a chance we might all be pleased or we might all be sad but one thing for sure it can only get better again IMHO.Shire is going forward big time imho.


http://www.sec.gov/Archives/edgar/data/1337905/000161577415000268/s100742_10q.htm

Series B Convertible Preferred Stock



The Series B Convertible Preferred Stock carries a cumulative dividend of 6% per annum and a stated value of $17.50 per share. Each share is convertible into 0.05 (pre-reverse split, 11.67) common shares based on the current conversion price of $375 (pre-reverse split, 1.50).



Series C Convertible Preferred Stock



The Series C Convertible Preferred Stock carries a cumulative dividend of 14% per annum and a stated value of $1,000 per share. Each share is convertible into 800 (pre-reverse split, 200,000) common shares based on the current conversion price of $1.25 (pre-reverse split, $0.005). During the six month periods ended December 31, 2014 and June 30, 2014, 1,070 and 350 shares were converted into 856,000 and 140,000 (pre-reverse split, 214,000,000 and 35,000,000) common shares, respectively.



Series D Convertible Preferred Shares



The Series D Convertible Preferred Stock carries a cumulative dividend of 8% per annum and a stated value of $1,000 per share. Each share is convertible into 800 (pre-reverse split, 200,000) common shares based on the current conversion price of $1.25 (pre-reverse split, 0.005). During the six month periods ended December 31, 2014 and June 30, 2014, zero and 300 shares were converted into zero and 120,000 (pre-reverse split, 30,000,000) common shares, respectively.









Series E Convertible Preferred Shares



The Series E Convertible Preferred Stock carries a cumulative dividend of 8% per annum and a stated value of $1,000 per share. Each share is convertible into 400 (pre-reverse split, 100,000) common shares based on the current conversion price of $2.50 (pre-reverse split, $0.01).



Series F Convertible Preferred Shares



On July 25, 2014, we entered into a stock purchase agreement with certain accredited investors whereby we issued 1,200 shares of Series F Convertible Preferred Stock and warrants to purchase 9,600,000 (pre-reverse split, 2.4 billion) shares of common stock (the “Financing”).



Each share of Series F Preferred Stock has a stated value and liquidation preference of $1,000, and accrues a dividend of 8% of the Stated Value per annum, and is convertible at any time into 4,000 (pre-reverse split, 1,000,000) common shares. The Series F Preferred holders vote together with holders of Common Stock on an as converted basis. The Warrants are exercisable for a period of five (5) years from the date of issuance and are exercisable into shares of Common Stock at an exercise price of $.25 (Pre-reverse split, $0.001) per share.